Erenumab-Aooe
Last Updated: 04/28/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 42 publications
A randomized, double blind, placebo-controlled pilot study to assess the efficacy of erenumab in individuals with temporomandibular disorder.
Journal: Journal of oral & facial pain and headache
Published: January 30, 2025
Changes in Use of Migraine Medications, Healthcare Resource Utilization, and Associated Direct Costs Over 12 Months Following Initiation of Erenumab: A US Retrospective Real-World Analysis.
Journal: Pain and therapy
Published: June 04, 2024
Zavegepant (Zavzpret) for acute treatment of migraine.
Journal: The Medical letter on drugs and therapeutics
Published: July 17, 2023
Comparison table: Some drugs for migraine prevention in adults.
Journal: The Medical letter on drugs and therapeutics
Published: June 02, 2023
Pharmacological characterisation of erenumab, Aimovig, at two calcitonin gene-related peptide responsive receptors.
Journal: British journal of pharmacology
Published: January 30, 2023
Atogepant (Qulipta) for migraine prevention.
Journal: The Medical letter on drugs and therapeutics
Published: January 27, 2022
A real-world, observational study of erenumab for migraine prevention in Canadian patients.
Journal: Headache
Published: December 13, 2021
Reduction in migraine pain intensity in patients treated with erenumab: A post hoc analysis of two pivotal randomized studies.
Journal: Cephalalgia : an international journal of headache
Published: August 19, 2021
Long-term efficacy and safety of erenumab in patients with chronic migraine in whom prior preventive treatments had failed: A subgroup analysis.
Journal: Headache
Published: August 12, 2021
Last Updated: 04/28/2026